We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+11.2%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.54B
AUM Growth
+$718M
Cap. Flow
-$27.8M
Cap. Flow %
-0.29%
Top 10 Hldgs %
34.85%
Holding
152
New
15
Increased
35
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$196M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$129M
3
GILD icon
Gilead Sciences
GILD
+$84.7M
4
VTRS icon
Viatris
VTRS
+$64.4M
5
BIIB icon
Biogen
BIIB
+$51.1M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$118M
2
PFE icon
Pfizer
PFE
+$98M
3
HCA icon
HCA Healthcare
HCA
+$97.1M
4
THC icon
Tenet Healthcare
THC
+$94.8M
5
AGN.PRA
Allergan plc
AGN.PRA
+$73.9M

Sector Composition

Rank Sector Weight
1 Healthcare 92.6%
2 Financials 1.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
26
Ironwood Pharmaceuticals
IRWD
$596M
$109M 1.14%
6,876,485
-1,769,627
-20% -$25.7M
ICPT
27
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$104M 1.09%
856,554
-180,446
-17% -$20.9M
AERI
28
DELISTED
Aerie Pharmaceuticals
AERI
$96.3M 1.01%
1,831,647
+335,647
+22% +$15.6M
SGYP
29
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$94.1M 0.99%
21,153,343
– –
ASND icon
30
Ascendis Pharma A/S
ASND
$16.6B
$93.5M 0.98%
3,367,315
+650,000
+24% +$17.2M
TMO icon
31
Thermo Fisher Scientific
TMO
$212B
$93.2M 0.98%
534,200
– –
BOLD
32
DELISTED
Audentes Therapeutics, Inc
BOLD
$91.9M 0.96%
4,801,638
– –
AGN
33
DELISTED
Allergan plc
AGN
$90.8M 0.95%
373,590
-103,800
-22% -$24.4M
SHPG
34
DELISTED
Shire pic
SHPG
$90.7M 0.95%
548,808
-348,643
-39% -$60.9M
BMRN icon
35
BioMarin Pharmaceuticals
BMRN
$11.9B
$89.2M 0.94%
982,600
-291,500
-23% -$26.5M
MGLN
36
DELISTED
Magellan Health Services, Inc.
MGLN
$88.6M 0.93%
1,215,100
+126,373
+12% +$8.88M
JAZZ icon
37
Jazz Pharmaceuticals
JAZZ
$16.1B
$84.9M 0.89%
545,900
+174,500
+47% +$26.7M
PFE icon
38
Pfizer
PFE
$144B
$82.6M 0.87%
2,591,575
-3,106,454
-55% -$98M
UNH icon
39
UnitedHealth
UNH
$385B
$79.5M 0.83%
428,600
+132,200
+45% +$23.2M
INSY
40
DELISTED
Insys Therapeutics, Inc.
INSY
$78.1M 0.82%
6,171,440
+100,000
+2% +$1.18M
MDT icon
41
Medtronic
MDT
$112B
$78M 0.82%
879,000
+112,400
+15% +$9.48M
AGN.PRA
42
DELISTED
Allergan plc
AGN.PRA
– –
-88,200
Closed -$73.9M
INSM icon
43
Insmed
INSM
$22.6B
$75.4M 0.79%
4,393,509
-417,396
-9% -$7.13M
GKOS icon
44
Glaukos
GKOS
$9.17B
$72.2M 0.76%
1,741,700
– –
ILMN icon
45
Illumina
ILMN
$29B
$69.1M 0.72%
409,658
+78,745
+24% +$13.6M
MNK
46
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$66M 0.69%
1,472,700
– –
CRVS icon
47
Corvus Pharmaceuticals
CRVS
$1.1B
$65.1M 0.68%
5,379,349
– –
VRAY
48
DELISTED
ViewRay, Inc.
VRAY
$61.2M 0.64%
9,458,567
– –
ACHN
49
DELISTED
Achillion Pharmaceuticals
ACHN
$60.2M 0.63%
13,107,200
– –
GBT
50
DELISTED
Global Blood Therapeutics, Inc.
GBT
$59.4M 0.62%
2,171,935
+1,087,435
+100% +$32.4M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2017 Portfolio in Review

As of Q2 2017, OrbiMed held 152 positions worth $9.54B, up 8.1% from $8.82B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed's Q2 2017 filing shows 15 new, 35 increased, 32 reduced and 15 closed positions. Its largest new stake was Cigna: 1,222,100 shares worth $205M. The largest sale was Centene, an estimated $118M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q2 2017 buy was Cigna: 1,222,100 shares worth $205M.
  • OrbiMed added most to Gilead Sciences in Q2 2017, an estimated $84.7M increase.
  • OrbiMed's biggest Q2 2017 reduction was Pfizer, cutting an estimated $98M.
  • OrbiMed fully exited Centene in Q2 2017, selling an estimated $118M.
  • OrbiMed's ten largest holdings make up 35% of its $9.54B portfolio in Q2 2017.
  • OrbiMed opened 15 new positions and closed 15 in Q2 2017.
  • OrbiMed's portfolio value rose 8.1% quarter-over-quarter to $9.54B.

Based on OrbiMed's 13F filing for Q2 2017, filed 14 Aug 2017.